All terms

    Physician Payments Sunshine Act

    U.S. law requiring disclosure of payments to physicians and teaching hospitals.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    The Sunshine Act (Open Payments program) requires manufacturers of drugs, devices, biologics, and medical supplies covered by Medicare/Medicaid/CHIP to report transfers of value to physicians, certain non-physician practitioners, and teaching hospitals. Reports go to CMS Open Payments each year and the data is published. Companies track payments for meals, consulting, travel and research, and reporting errors can lead to civil penalties.
    What the regulation says
    The Physician Payments Sunshine Act, also known as the Open Payments program, mandates that applicable manufacturers report payments and other transfers of value made to covered recipients to the Centers for Medicare & Medicaid Services (CMS), as detailed in 42 CFR Part 403, Subpart I. This regulation aims to increase transparency regarding financial relationships between the healthcare industry and healthcare providers, aligning with broader transparency initiatives from bodies like the FDA regarding medical device marketing practices.

    What this means in practice

    Reported annually by CMS and publicly searchable. Mis-reporting creates reputational and enforcement risk; KOL agreements must be FMV and well-documented.

    Examples

    • A medical device company pays a surgeon a consulting fee for their expertise in developing a new surgical tool, requiring this payment to be reported to CMS.
    • A pharmaceutical manufacturer sponsors a physician's travel and accommodation to attend an educational conference where their drug is discussed, necessitating disclosure under the Open Payments program.
    • A MedTech company provides a research grant to a teaching hospital for a study involving their diagnostic equipment, which then must be reported to CMS.
    Common pitfalls
    • •Failing to accurately categorize transfers of value can lead to misreporting and penalties.
    • •Inadequate documentation of fair market value for key opinion leader (KOL) agreements can result in non-compliance.
    • •Overlooking indirect payments or transfers of value made through third parties can lead to enforcement actions.
    • •Not understanding the specific definitions of "applicable manufacturer" and "covered recipient" can lead to reporting errors.

    Frequently asked questions

    Manufacturers must report a broad range of transfers of value, including consulting fees, research grants, meals, travel, educational items, and charitable contributions, if they exceed certain thresholds outlined by CMS.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Latest in MedTech

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2
    Link health: 3 verified· last checked 2026-06-20
    CMS·1AdvaMed·1AHRMM·1
    1. 1
      CMS Open Payments
      Tier 2 Verified
      CMScms.gov
    2. 2
      AdvaMed Code of Ethics
      Tier 4 Verified
      AdvaMedadvamed.org
    3. 3
      AHRMM - Healthcare Supply Chain
      Tier 4 Verified
      AHRMMahrmm.org

    Inline markers like [1] jump to the matching reference above.